Hardboy
24 Mar 2017
Re: UpDown "3 reasons for fall""dir sale 43k " - valid, but after the amount of shares bought by directors over the winter, as has been pointed out, this is minute. And it was falling pretty seriously before the announcement. "Trump" - yes, but the rest of the sector is not behaving this way. "sell in I. C." - I wasn't aware of that; and yes it is amazing what an effect an IC recommendation has on share prices. However, again, the price was in slalom mode before it came out. So, I maintain, given the initial reaction to the results the subsequent anti-reaction is illogical.
bamboozled
24 Mar 2017
Re: UpDown This time last year,HIK dropped to around £16 after results and I bought in.Unfortunately it marched all the way up to about £25 and I didn't take profit and it came back down.This time it marched up to about £22 and has started to drop so time to bale for me. I may buy in again at lower levels but long term growth doesn't look good.Who knows though,shares behave oddly at the best of times! The proceeds gone into my 'looking for bargains' pot -maybe next week when Brexit starts.
sapito
24 Mar 2017
Re: UpDown Relentless drop looks very odd. Broker forecasts are all over the place: the lowest is HSBC's £18, but Barclays still haven't revised their target of £34 from Dec 16. They can't all be right! BTW, director's sale is modest by Hikma's standards - seller still owns £7.5m worth, so still plenty of skin in the game. Worth continuing to hold at current price, I think. People have speculated about a takeover: would be very nice, but I can't see it TBH (perhaps Barclays can!)
paul1945
24 Mar 2017
Re: UpDown Still a holder but 3 reasons for fall dir sale 43k , Trump & sell in I. C.
Hardboy
24 Mar 2017
Re: UpDown Not sure what negative sentiment you mean - I've not read a negative comment for ages. Though a director sale doesn't help. But this is getting silly again. Results were received positively, and press & broker comments since then have all been positive, but we are now sliding fast. I would have liked to show the graph against the sector (which can be done on charts) to show this fall is company specific.
bamboozled
24 Mar 2017
Re: UpDown Sold up yesterday,took a small profit with the last tranche.Wish I had sold when it was around £22 after recent finals.Too much of a downtrend now given negative sentiment for HIK.Will watch on the sidelines and may buy back if it gets around £16/17.Watch it bounce back up now lol.
Hardboy
21 Mar 2017
Re: UpDown Absolutely.The market reacted very positively the day the finals were released, which surprised me - nearly 8% rise in the day. And this generated a lot of very positive press and broker comments. Since when it has been down hill all the way, and the gains on the day have been wiped out, and turned to losses. I do not understand.
bamboozled
16 Mar 2017
UpDown The market giveth and it take away. A downgrade from JP but still above the current SP.Jeeez, can't win...... Great rise yesterday and followed by a fall(hopefully temporarily)."JP Morgan Cazenove downgraded Hikma Pharmaceuticals to 'neutral' as it expects the company's new asthma drug to have a short term impact.The bank downgraded the FTSE 100 company to 'neutral' from 'overweight' but raised it price target to 2,400p from 2,100p after a review of its generic version of the asthma drug Advair, which is forecast to add about 7% growth to earnings per share in 2018, however a more rapid erosion is excepted from 2019 onward.JP Morgan took a more cautious long-term view as it expects continued pricing pressure and likely further generic entrants into a category with modest growth, so its sees the contribution by Advair declining after 2018.The downgrade came despite Hikma reporting a set of first half results that beat expectations, although it did post guidance for this year that needed a 5% reduction to 2017 consensus.With Hikma's shares up 20% for the year to date against the FTSE 100's growth of 3% and the Stoxx Europe 600 healthcare index's growth of 5%, the bank believes that this includes a market approval of Adavir.Even on its upgraded 2018 earnings per share, assuming the launch of the drug will definitely go ahead later this year, Hikma now trades on 15 times the 2018 price-earnings ratio."We see this multiple offering limited room for further re-rating, with generic Advair being a finite opportunity, and with limited visibility on the long-term growth rate."Shares in Hikma Pharmaceutical were down 1.22% to 2,269.44p at 0801 GMT."
caesat
15 Mar 2017
Re: Finals see ftlalphaville for Barclays note.Thanks
Hardboy
15 Mar 2017
Re: Finals It's not unusual for me to misread markets! (In this case I'm quite pleased.)
bamboozled
15 Mar 2017
Re: Finals Looks like the market likes it!
Hardboy
15 Mar 2017
Finals Hard to assess the finals without far more study because of the transitions during the year; but the bottom line is core operating profits at constant exchange rates were up 14%; which is OK. Still plenty of headwinds, but a lot of new products in the market & more on the way; so there should be more growth to come. Having said that I'm sure the market will open down. There's bound to be something there to unsettle investors.
Hardboy
12 Feb 2017
Re: Update Thanks for the update Fred, and glad you can tear yourself away from winding everybody up on the IGG board. (They don't like you there do they? What a shame iii did away with the red ticks, you'd be setting records.)
Fred Prior
11 Feb 2017
Update Hi guys, have been busy with projects recently but FYI I just came off the phone with the spread better and as we have not spoke for a few weeks since he sold out, he informed me that he had put a new position on at around the current SP in the middle of January, needless to say it would appear the share price is reluctant to climb much above 1950p and as soon as it goes above it immediately gets sold into. I asked him why did he reenter when the company is trading against him and his reply was what will be happening in the near future that nobody will be able to suppress the price.Make of that what you will and I for one are starting to show a decent overall profit and I will be a buyer again should be break above the 1950 level with volume.Good luck and lets hope we can reach or exceed last years highs of 2700p in due course!!I am recommending a hold from the recent news as who knows if the "manipulators" won't attempt another shake out, although the person stated his position was not as large as previous.
paul1945
08 Feb 2017
Re: Holding Thanks
